MEVACOR (LOVASTATIN) APPROVAL AFTER NINE-MONTH FDA REVIEW ILLUSTRATES MERCK'S DEVELOPMENT STRENGTH; POTENTIAL U.S. POPULATION COULD EXCEED 10 MIL.

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".